Simcere Pharmaceutical Group Limited
SMHGF
$0.6697
-$0.0641-8.74%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -12.89% | -6.87% | -0.20% | 6.54% | 16.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.89% | -6.87% | -0.20% | 6.54% | 16.59% |
| Cost of Revenue | -11.86% | 1.29% | 16.98% | 19.48% | 25.12% |
| Gross Profit | -13.19% | -9.15% | -4.76% | 3.09% | 14.31% |
| SG&A Expenses | -16.16% | -10.26% | -3.72% | 3.09% | 12.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 17.11% | 18.84% | 20.49% | 17.84% | 13.46% |
| Total Operating Expenses | -18.97% | -10.65% | -1.31% | 6.82% | 18.48% |
| Operating Income | 53.89% | 31.38% | 10.10% | 4.03% | -0.76% |
| Income Before Tax | -133.08% | -106.44% | -8.76% | 106.71% | 214.12% |
| Income Tax Expenses | -39.49% | 299.39% | 166.40% | 139.91% | 125.92% |
| Earnings from Continuing Operations | -133.69% | -107.37% | -15.73% | 92.02% | 189.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | -89.00% | -80.90% | -67.96% | -59.90% |
| Net Income | -133.66% | -107.34% | -16.03% | 91.08% | 187.55% |
| EBIT | 53.89% | 31.38% | 10.10% | 4.03% | -0.76% |
| EBITDA | 38.44% | 22.34% | 6.85% | 2.53% | -0.19% |
| EPS Basic | -133.62% | -107.62% | -17.54% | 89.73% | 186.09% |
| Normalized Basic EPS | 55.00% | 36.27% | 17.14% | -0.89% | -15.25% |
| EPS Diluted | -133.84% | -108.14% | -18.58% | 90.14% | 187.60% |
| Normalized Diluted EPS | 55.00% | 36.27% | 17.14% | -0.89% | -15.25% |
| Average Basic Shares Outstanding | -1.57% | -0.84% | -0.10% | 0.10% | 0.29% |
| Average Diluted Shares Outstanding | -1.94% | -1.09% | -0.25% | 0.07% | 0.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -4.07% | -15.08% | 0.23% | -0.50% | -0.68% |